首页> 外文OA文献 >Pharmacoeconomic analysis of combination of daclatasvir and sofosbuvir in treatment of chronic hepatitis C(genotype 3) in the Russian Federation: among treatmentexperienced patients

【2h】

Pharmacoeconomic analysis of combination of daclatasvir and sofosbuvir in treatment of chronic hepatitis C(genotype 3) in the Russian Federation: among treatmentexperienced patients

机译：俄罗斯联邦慢性丙型肝炎（基因型3）治疗慢性丙型肝炎（基因型3）的药物经济分析：治疗经验性患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A.Yu. Kulikov; V.V. Babiy;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis [J] . Jan Sperl, Sona Frankova, Miluse Kreidlova, Therapeutics and Clinical Risk Management . 2017,第5期

机译：联合索非布韦和达卡他韦治疗维持性血液透析患者的基因型3型慢性丙型肝炎病毒感染
2. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients [J] . Current drug safety . 2020,第1期

机译：Ledipasvir / Sofosbuvir与Daclatasvir / Sofosbuvir治疗慢性丙型肝炎基因型4例患者
3. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy [J] . Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, The European journal of health economics: HEPAC : health economics in prevention and care . 2018,第1期

机译：Daclatasvir + Sofosbuvir +利巴韦林（16周和12周）使用的成本效益分析与Sofosbuvir +利巴韦林（16周和24周）治疗意大利丙型肝炎病毒基因型3的肝硬化患者治疗
4. Genotype and Serotype Identification of Hepatitis B Virus in Chronic Hepatitis B Patients Treated with Telbivudine [C] . Y Purnamasari, Tien, Arimaswati, International Seminar on Smart Molecule of Natural Resources . 2020

机译：临床治疗慢性乙型肝炎患者乙型肝炎病毒的基因型和血清型鉴定
5. Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States. [D] . Vutien, Philip. 2016

机译：慢性丙型肝炎的治疗率存在种族差异：在美国以人群为基础的队列研究，共73665名患者。
6. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis [O] . Jan Sperl, Sona Frankova, Miluse Kreidlova, 2017

机译：索非布韦和达拉他韦联合治疗维持性血液透析患者的基因型3型慢性丙型肝炎病毒感染
7. Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial [O] . Mostafa Yakoot, Alaa M. Abdo, Siham Abdel-Rehim, 2017

机译：响应量身定制的方案与埃及慢性丙型肝炎患者基因型-4感染的双索非布韦/达卡他韦治疗的12周固定疗程：随机，开放标签，非劣效性试验

Pharmacoeconomic analysis of combination of daclatasvir and sofosbuvir in treatment of chronic hepatitis C(genotype 3) in the Russian Federation: among treatmentexperienced patients

著录项

引文网络

相似文献

相关主题

期刊订阅